| Статус: | Recruiting |
| Фаза: | Phase 2 |
| Начало: | 3 июня 2024 г. |
| Окончание: | 31 декабря 2025 г. |
| Описание: | Refralon® tablets in two different doses (1 or 2 tablets per day) will be evaluated vs. placebo in patients with persistent atrial fibrillation/flutter after synus rhythm restoration in order to prevent recurrence of arrhythmia. Efficacy and safety of Refralon® tablets will be studied, its optimal dose will be selected and its pharmacokinetics will be evaluated in 14 days, 1, 3 and 6 months. |
| смотреть на ClinicalTrials.gov |
| Статус: | Completed |
| Фаза: | Phase 2 |
| Начало: | 1 марта 2008 г. |
| Окончание: | 1 декабря 2009 г. |
| Описание: | To evaluate the effects of K201 on sinus rhythm restoration, symptom score, various cardiovascular parameters, and safety. |
| смотреть на ClinicalTrials.gov |